Search results
Results from the WOW.Com Content Network
The EMA also initiated an assessment for all COVID‑19 vaccines used in the EU for immune thrombocytopenia (ITP), described as low blood platelet levels that could lead to bruising and bleeding, as a possible side effect, whilst also stating that up to this point no link with any COVID‑19 had been established. [12]
Health Canada received a submission from Moderna on June 29, 2023 for yet another reformulated COVID-19 vaccine based on the Omicron XBB.1.5 subvariant of SARS-CoV-2. [131] The updated version was tested in a small human trial of 101 participants who had previously received four doses of previous formulations of the Moderna COVID-19 vaccine.
Tainted blood disaster; Part of Contaminated haemophilia blood products: Date: late 1970s – 1980s: Location: Canada: Also known as: Tainted blood scandal: Type: public health crisis and scandal: Outcome: creation of Héma-Québec and Canadian Blood Services: Deaths: 8,000: Inquiries: Commission of Inquiry on the Blood System in Canada ...
A BBC Radio presenter who died in May after receiving her first shot of the Oxford-AstraZeneca coronavirus vaccine fell prey to extremely rare blood clots resulting from the jab, a coroner has found.
An academic study purporting to find 278,000 deaths from COVID vaccinations thrilled the anti-vaccine crowd. The failings that led to its retraction have a lot to teach us about bogus science.
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 , the virus that causes coronavirus disease 2019 . The COVID‑19 vaccines are widely credited for their role in reducing the spread of COVID‑19 and reducing the severity and death caused by COVID‑19.
European pharma giant AstraZeneca Plc’s (NASDAQ:AZN) Covid vaccine, developed with the University of Oxford, is facing a class action lawsuit alleging its vaccine caused death and serious injury ...
In December 2020, Health Canada approved clinical trials for a new COVID-19 subunit vaccine developed by the University of Saskatchewan Vaccine and Infectious Disease Organization–International Vaccine Centre (VIDO–InterVac), which were expected to begin in January 2021 at the Canadian Center for Vaccinology in Halifax as a combined phase 1 ...